Equities

LENSAR Inc

LNSR:NAQ

LENSAR Inc

Actions
  • Price (USD)7.38
  • Today's Change0.00 / 0.00%
  • Shares traded57.39k
  • 1 Year change+225.11%
  • Beta0.6701
Data delayed at least 15 minutes, as of Nov 11 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

LENSAR, Inc. is a commercial-stage medical device company. The Company is focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its product portfolio consists of the LENSAR Laser System and ALLY Adaptive Cataract Treatment System (ALLY System) and its associated consumable components. The system incorporates a range of technologies designed to assist the surgeon in obtaining visual outcomes. The consumable portion of the system consists of a disposable patient interface device kit. The ALLY System is designed to combine its femtosecond laser technology features with enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room or in-office surgical suite. Its system is used across surgeons, hospital outpatient surgical facilities and ambulatory surgery centers.

  • Revenue in USD (TTM)45.12m
  • Net income in USD-12.56m
  • Incorporated2004
  • Employees130.00
  • Location
    LENSAR Inc2800 Discovery Drive, Suite 100ORLANDO 32826United StatesUSA
  • Fax+1 (302) 655-5049
  • Websitehttps://www.lensar.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
IR-Med Inc0.00-3.47m60.48m6.00--166.52-----0.0499-0.04990.000.00510.00----0.00-197.95---273.36--------------0.3019-------3.70------
Pheton Holdings Ltd628.59k-241.22k61.42m11.00--168.87--97.71-0.0201-0.02010.05240.0255------57,144.55--------74.90---38.37--0.3984--0.00---7.53---387.24------
Alpha Pro Tech, Ltd.61.09m4.71m61.81m124.0013.691.0110.921.010.41060.41065.325.580.89171.737.25492,653.206.8815.217.0716.0639.2940.237.7112.9317.19--0.000.00-1.215.6027.642.935.50--
Heartbeam Inc0.00-16.91m68.26m15.00--7.84-----0.6375-0.63750.000.32780.00----0.00-106.50---113.62--------------0.00-------12.94------
Hyperfine Inc11.94m-41.45m68.99m131.00--1.03--5.78-0.5773-0.57730.16630.92480.12620.98562.5691,160.30-43.81---48.08--44.51---347.05--7.24--0.00--61.90--39.54------
Vivani Medical Inc0.00-24.20m69.62m44.00--2.92-----0.4643-0.46430.000.43160.00----0.00-44.89-56.58-50.97-67.66-------2,868.72----0.00-------84.69--40.33--
Monogram Technologies Inc365.00k-11.69m70.06m28.00--9.94--191.95-0.3745-0.37450.01180.22240.0239----13,035.71-76.61-119.26-117.14-257.400.00---3,203.87-5,045.60----0.00-------0.3964---15.97--
Modular Medical Inc0.00-17.87m71.96m39.00--8.98-----0.6986-0.69860.000.24620.00----0.00-150.56-187.51-167.12-234.72------------0.00-------25.87--85.63--
Xtant Medical Holdings Inc110.94m-3.33m72.89m207.00--1.52127.430.657-0.0284-0.02840.84310.34541.381.406.35535,956.50-4.15-10.38-5.77-14.6861.6161.08-3.00-8.661.01-4.540.429--57.504.81107.78--18.47--
Owlet Inc65.64m-15.92m75.47m76.00------1.15-1.89-1.897.61-2.291.273.484.39863,618.40-20.24---165.32--45.71---15.91--0.8168-40.50-----21.95--52.74------
Baird Medical Investment Holdings Ltd0.00-4.88m77.85m----8.74-----0.7412-0.74120.000.34340.00-------14.19---20.29--------------0.3413-------627.59------
Work Medical Technology Group Ltd13.57m112.03k82.74m216.00734.468.3250.936.100.00770.00770.93560.68110.48892.104.1062,805.320.2284--0.6332--30.54--0.4673--0.92651.120.4459---31.18---87.05------
LENSAR Inc45.12m-12.56m85.67m130.00--3.60--1.90-1.11-1.113.923.240.68061.259.08347,107.70-18.94-30.97-22.49-36.9449.8751.04-27.83-52.302.15--0.00--19.2511.5727.77---42.91--
electroCore, Inc.21.28m-14.23m86.97m68.00--7.58--4.09-2.19-2.193.251.781.161.4154.85312,955.90-77.78-70.73-125.05-88.9683.6175.81-66.84-352.822.12--0.00--86.5774.4215.02---5.88--
Edap Tms SA (ADR)66.50m-21.08m95.17m307.00--1.86--1.43-0.5685-0.56851.791.380.69922.373.42216,625.80-22.16-6.62-31.50-9.2240.3443.23-31.69-9.591.80--0.0599--9.649.05-622.06--32.75--
Fonar Corp102.89m9.91m100.86m520.0010.460.60774.480.98041.441.4415.0224.730.49621.851.37197,855.906.807.307.097.8743.8747.1313.7014.507.71--0.0047--4.303.3612.58-7.16-25.07--
Data as of Nov 11 2024. Currency figures normalised to LENSAR Inc's reporting currency: US Dollar USD

Institutional shareholders

38.77%Per cent of shares held by top holders
HolderShares% Held
North Run Capital LPas of 07 May 20241.10m9.48%
Park West Asset Management LLCas of 30 Jun 2024973.41k8.39%
Dimensional Fund Advisors LPas of 30 Sep 2024633.57k5.46%
The Vanguard Group, Inc.as of 30 Jun 2024430.30k3.71%
Brandes Investment Partners LPas of 30 Jun 2024373.20k3.22%
Renaissance Technologies LLCas of 30 Jun 2024327.05k2.82%
DCF Capital LLCas of 30 Jun 2024241.48k2.08%
Clearline Capital LPas of 30 Jun 2024173.00k1.49%
BlackRock Fund Advisorsas of 30 Jun 2024151.21k1.30%
Geode Capital Management LLCas of 30 Jun 202497.01k0.84%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.